Medicannabis, therapeutic cannabis: treatments and use

Could CBD be an anitbiotic?

The relationship in between infection and traditional prescription antibiotics

Could CBD be useful in the battle against resistant bacterial strains? The results from the University of Queensland in Australia suggest that it is possible. But before examining the research study in depth, it works to comprehend the advancement of the relationship in between bacteria and prescription antibiotics.

Because the revolutionary discovery of penicillin by Alexander Fleming in 1928, prescription antibiotics have been an important tool in the battle against bacteria and infections. And although we still use the very same tested approaches today, bacteria have evolved. When exposed to prescription antibiotics, specific bacteria, fungi and parasites have the ability to adapt and cancel the efficiency of the drug by establishing resistance.

It’s worth explaining that antimicrobial resistance was most likely to happen anyway, as the hereditary code for bacteria modifications gradually. Nevertheless, it is thought that the overuse of prescription antibiotics is an essential factor that accelerates the advancement of resistant strains.

According to the World Health Organization, antimicrobial resistance “is a significantly major danger to international public health that needs action in all sectors of government and in society.” This has led scientists to think outside the box by attempting to identify compounds that could be useful in the battle against hazardous bacteria. One of these compounds is cannabidiol (CBD), a cannabinoid discovered in Cannabis sativa.

Researchers are looking for new methods to attack infections and resistant bacteria.

Dr. Mark Blaskovich, Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery and Senior Research Officer at the Institute for Molecular Bioscience at the University of Queensland, concluded that CBD anything works against Gram-positive bacteria. Stress of Gram-positive bacteria include Staphylococcus aureus (common in skin infections) and Streptococcus pneumoniae (common in bacterial pneumonia).

Dr. Blaskovich presented his findings at an annual meeting of the American Society for Microbiology. In vitro samples of both kinds of gram-positive bacteria were treated with synthetic CBD. The outcomes led Dr. Blaskovich to the conclusion that CBD operates at levels similar to those of prescription antibiotics vancomycin and daptomycin. He also discovered that CBD appeared to work against gram-positive strains of resistant bacteria, which numerous conventional prescription antibiotics are beginning to stop working.

” In particular, the activity was selected against the resistant strains of Staphylococcus aureus (MRSA, VISA, SARV), Streptococcus pneumoniae (MDR), and Enterococcus faecalis (ERV). Cannabidiol was bactericidal, had a low propensity to cause resistance and was active against MRSA biofilms. “

The group also conducted another research study utilizing topical CBD to treat a skin infection in mice. Once again, although the outcomes were positive, CBD did not appear to get rid of the infection, however simply to minimize the number of bacterial cells.

Could CBD end up being an antibiotic?

While it is easy to hail this work as a significant advancement in the antibacterial capabilities of CBD, it is too soon to quit on penicillin.

Although it is thought that the efficiency of CBD could originate from the method it attacks the biofilm surrounding bacterial cells, the authors are still uncertain of the mechanism of action of CBD. They also did not think twice to mention the drawbacks of the research study. Dr. Blaskovich pointed out that since the outcomes remain in the initial phases, it is far too early for people to start treating their CBD infections themselves.

The research study was also conducted in vitro (outside the human body), and there is a threat that the outcomes of scientific trials will not be the same. Several compounds have revealed antibacterial efficacy in petri meals, however then failed at this vital stage. It should also be pointed out that the two research studies were performed in cooperation with Botanix Pharmaceuticals Ltd, a pharmaceutical company focusing on topical CBD Culture products.

Nevertheless, this research could be an essential advance for CBD and the battle against antimicrobial resistance. CBD continues to have a good security profile and is not considered hazardous even in large amounts. Fortunately, Dr. Blaskovich and his group strategy to continue their research.

Scroll to top